Skip to content

Study · Systematic review · 2022

14 results

The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.

Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, Wang L, Yang H, Gong F

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme5 May 2022Cited by 38 (Europe PMC)

PMID35512849 (opens in a new tab)DOI10.1055/a-1844-1176 (opens in a new tab)PepBankPUB-35512849
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In the subgroup analysis, semaglutide showed the most obvious antiobesity effect in weight loss among the GLP-1 receptor agonists.

    In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide gave the largest weight loss among the GLP-1 drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, semaglutide subgroup
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The subgroup analysis showed that semaglutide displayed the most obvious antiobesity effect in terms of weight loss, the reduction of body mass index (BMI) and waist circumference (WC).
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.
  2. 02HumanSystematic reviewEfficacy outcome

    In the subgroup analysis, semaglutide showed the most obvious reduction in body mass index among the GLP-1 receptor agonists.

    In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide lowered BMI most among the GLP-1 drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction, semaglutide subgroup
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The subgroup analysis showed that semaglutide displayed the most obvious antiobesity effect in terms of weight loss, the reduction of body mass index (BMI) and waist circumference (WC).
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.
  3. 03HumanSystematic reviewEfficacy outcome

    In the subgroup analysis, semaglutide showed the most obvious reduction in waist circumference among the GLP-1 receptor agonists.

    In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide reduced waist size most among the GLP-1 drugs compared.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference reduction, semaglutide subgroup
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The subgroup analysis showed that semaglutide displayed the most obvious antiobesity effect in terms of weight loss, the reduction of body mass index (BMI) and waist circumference (WC).
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.
  4. 04HumanSystematic reviewSafety outcome

    In the subgroup analysis, semaglutide had the lowest risk of gastrointestinal adverse events among the three GLP-1 receptor agonists.

    In plain wordsIn adults with overweight or obesity and no diabetes, semaglutide had the lowest risk of stomach and gut side effects among three GLP-1 drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseGastrointestinal adverse events, semaglutide subgroup
    Study

    n: not reported in source

    Comparator
    Liraglutide and exenatide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The subgroup analysis also represented that semaglutide displayed the lowest risk of gastrointestinal adverse events among three kinds of GLP-1RAs.
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including liraglutide gave greater weight loss than placebo.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including liraglutide led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −5.39 NA
    GLP-1RAs vs placebo

    Source sentences

    Summary
    significantly achieved greater weight loss than placebo [WMD=-5.39, 95% CI (-6.82, -3.96)]
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including semaglutide gave greater weight loss than placebo.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including semaglutide led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −5.39 NA
    GLP-1RAs vs placebo

    Source sentences

    Summary
    significantly achieved greater weight loss than placebo [WMD=-5.39, 95% CI (-6.82, -3.96)]
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including liraglutide gave greater weight loss than metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including liraglutide led to more weight loss than metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss versus metformin
    Study

    n: not reported in source

    Comparator
    Metformin
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −5.46 NA
    GLP-1RAs vs metformin

    Source sentences

    Summary
    and metformin [WMD=-5.46, 95% CI (-5.87, -5.05)]
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including semaglutide gave greater weight loss than metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including semaglutide led to more weight loss than metformin.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss versus metformin
    Study

    n: not reported in source

    Comparator
    Metformin
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    WMD
    −5.46 NA
    GLP-1RAs vs metformin

    Source sentences

    Summary
    and metformin [WMD=-5.46, 95% CI (-5.87, -5.05)]
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including liraglutide reduced BMI more than placebo or metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including liraglutide lowered BMI more than placebo or metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI reduction versus placebo or metformin
    Study

    n: not reported in source

    Comparator
    Placebo or metformin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including semaglutide reduced BMI more than placebo or metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including semaglutide lowered BMI more than placebo or metformin.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction versus placebo or metformin
    Study

    n: not reported in source

    Comparator
    Placebo or metformin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including liraglutide reduced waist circumference more than placebo or metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including liraglutide reduced waist size more than placebo or metformin.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference reduction versus placebo or metformin
    Study

    n: not reported in source

    Comparator
    Placebo or metformin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including semaglutide reduced waist circumference more than placebo or metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including semaglutide reduced waist size more than placebo or metformin.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference reduction versus placebo or metformin
    Study

    n: not reported in source

    Comparator
    Placebo or metformin
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP-1RA had a superior antiobesity effect than placebo/Met in overweight/obese patients without diabetes in terms of body weight, BMI, and WC
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 13HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including liraglutide caused more gastrointestinal adverse events, such as nausea and vomiting, than placebo and metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including liraglutide caused more nausea and vomiting than placebo and metformin.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal adverse events versus placebo and metformin
    Study

    n: not reported in source

    Comparator
    Placebo and metformin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    However, GLP-1RAs treatments had more gastrointestinal adverse events (such as nausea and vomiting) than placebo and Met.
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 14HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In overweight or obese adults without diabetes, pooled GLP-1 receptor agonists including semaglutide caused more gastrointestinal adverse events, such as nausea and vomiting, than placebo and metformin.

    In plain wordsIn adults with overweight or obesity and no diabetes, GLP-1 drugs including semaglutide caused more nausea and vomiting than placebo and metformin.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal adverse events versus placebo and metformin
    Study

    n: not reported in source

    Comparator
    Placebo and metformin
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    However, GLP-1RAs treatments had more gastrointestinal adverse events (such as nausea and vomiting) than placebo and Met.
    2 context sentences
    Summary · context
    Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in overweight/obese patients without diabetes.
    Summary · context
    A total of 24 RCTs were recruited in the present analysis which included 5867 patients.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.